Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3–6
UF startup Rise Therapeutics announced that it will report its first clinical results from the completed dose escalation segment of its R-3750 Phase 1 clinical trial in ulcerative colitis at the upcoming DDW conference.
Rise Therapeutics Receives FDA IND Clearance To Initiate Clinical Testing of R-5780 in Cancer
UF startup Rise Therapeutics announced that the U.S. FDA has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780.
Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials
UF startup Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials.
New Funding Secured To Support Clinical GMP Manufacturing Expansion at Rise Therapeutics
UF Startup Rise Therapeutics announced that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health (NIH).
First Type 1 Diabetes Patient Enrolled in Rise Therapeutics’ Latest Clinical Trial
Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced it has enrolled its first patient in its R-5280 placebo-controlled, blinded, Phase 1b type 1 diabetes clinical trial.
First Patient Enrolled in Rise Therapeutics’ Rheumatoid Arthritis Clinical Trial
Rise Therapeutics, a UF startup and a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced it has enrolled its first patient in its R-2487 Phase 1 rheumatoid arthritis clinical trial.